Pharmacoeconomic research partnerships should be attractive to industry, OTA's Wagner says.
Executive Summary
PHARMACOECONOMIC RESEARCH PARTNERSHIPS -- WITH NO VETO FOR MARKETERS -- are in "pharmaceutical companies' best interests," Office of Technology Assessment Senior Associate Judith Wagner maintained in a presentation to the Biotechnology Industry Organization annual meeting May 24 in San Francisco. Drug companies will increasingly find it to their advantage to "help fund independent buyer-led studies of cost-effectiveness analyses," in light of recent FDA suggestions that pharmacoeconomic claims by manufacturers will likely require two adequate well-controlled trials, Wagner suggested.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth